Replication-competent viruses, such as Vaccinia virus (VACV), are powerful tools for the development of oncolytic viral therapies and elicit superior immune responses when used as vaccine and immunotherapeutic vectors. However, severe complications from uncontrolled viral replication can occur, particularly in immunocompromised individuals or in those with other predisposing conditions. VACVs constitutively expressing interferon-γ (IFN-γ) replicate in cell culture indistinguishably from control viruses; however, they replicate in vivo to low or undetectable levels, and are rapidly cleared even in immunodeficient animals. In an effort to develop safe and highly effective replication-competent VACV vectors, we established a system to inducibly express IFN-γ. Our SMART (safety mechanism assisted by the repressor of tetracycline) vectors are designed to express the tetracycline repressor under a constitutive VACV promoter and IFN-γ under engineered tetracycline-inducible promoters. Immunodeficient SCID mice inoculated with VACVs not expressing IFN-γ demonstrated severe weight loss, whereas those given VACVs expressing IFN-γ under constitutive VACV promoters showed no signs of infection. Most importantly, mice inoculated with a VACV expressing the IFN-γ gene under an inducible promoter remained healthy in the presence of doxycycline, but exhibited severe weight loss in the absence of doxycycline. In this study, we developed a safety mechanism for VACV based on the conditional expression of IFN-γ under a tightly controlled tetracycline-inducible VACV promoter for use in vaccines and oncolytic cancer therapies.
Replication-competent viruses, such as Vaccinia virus (VACV), are powerful tools for the development of oncolytic viral therapies and elicit superior immune responses when used as vaccine and immunotherapeutic vectors. However, severe complications from uncontrolled viral replication can occur, particularly in immunocompromised individuals or in those with other predisposing conditions. VACVs constitutively expressing interferon-γ (IFN-γ) replicate in cell culture indistinguishably from control viruses; however, they replicate in vivo to low or undetectable levels, and are rapidly cleared even in immunodeficient animals. In an effort to develop safe and highly effective replication-competent VACV vectors, we established a system to inducibly express IFN-γ. Our SMART (safety mechanism assisted by the repressor of tetracycline) vectors are designed to express the tetracycline repressor under a constitutive VACV promoter and IFN-γ under engineered tetracycline-inducible promoters. Immunodeficient SCID mice inoculated with VACVs not expressing IFN-γ demonstrated severe weight loss, whereas those given VACVs expressing IFN-γ under constitutive VACV promoters showed no signs of infection. Most importantly, mice inoculated with a VACV expressing the IFN-γ gene under an inducible promoter remained healthy in the presence of doxycycline, but exhibited severe weight loss in the absence of doxycycline. In this study, we developed a safety mechanism for VACV based on the conditional expression of IFN-γ under a tightly controlled tetracycline-inducible VACV promoter for use in vaccines and oncolytic cancer therapies.
T he advances brought about by molecular biology and genetic engineering have turned viruses into powerful tools for the development of vaccines and cancer therapies. Replicationcompetent viral vectors used in vaccine development, immunotherapy, and oncolytic cancer therapy include retroviruses, adenoviruses, adeno-associated viruses, herpesviruses, and poxviruses (1) (2) (3) . Vaccinia virus (VACV), the prototype member of the genus Orthopoxvirus, family Poxviridae, has been used extensively as a vector for the development of recombinant live vaccines and cancer therapies (4) . The safety of these live recombinant vectors is always a concern, however, as uncontrolled replication can result in complications from vaccination or therapeutic use.
Although VACV has not been associated with any disease, it can cause mild to severe complications, particularly in immunodeficient or immunosuppressed individuals, including accidental infection, generalized vaccinia, postvaccinial encephalitis, progressive vaccinia, and eczema vaccinatum (5) (6) (7) (8) (9) . These complications have been correlated with preexisting conditions such as atopic dermatitis, immunosuppression (e.g., owing to HIV/AIDS or immunosuppressive drug therapy), and cardiac disease. Individuals with such conditions or with contacts with such conditions are contraindicated for vaccination or treatment with replicationcompetent VACVs (10, 11) .
In an effort to develop safer yet highly effective live viral vectors, we constructed replication-competent VACV vectors with a safety mechanism that can be activated to stop therapy and ameliorate vector complications, and performed proof-ofprinciple studies in vitro and in vivo. These SMART (safety mechanism assisted by the repressor of tetracycline) viral vectors use elements from the tet operon to regulate the expression of a gene that can stop viral replication in vivo. VACV is an ideal vector system for testing this strategy, given that the transposon Tn10 tet operon has been successfully adapted to VACV (12) , allowing the regulation of gene expression by tetracycline antibiotics, such as doxycycline (DOX). In addition, interferon-γ (IFN-γ) leads to virus clearance in vivo when expressed by VACV, attenuating the virus by more than 1 million-fold (13) (14) (15) (16) .
Here we report the development of VACV vectors inducibly expressing IFN-γ that are replication-competent and highly safe. We demonstrated the proof of this concept using antibiotic therapy to protect immunodeficient SCID mice from lethal VACV infection.
Results
Inducible Expression by tet Operon-Controlled Promoters in VACV. In the tet operon regulatory system previously adapted to VACV, the tetracycline repressor (TetR) is expressed constitutively, and in the absence of tetracyclines, binds to a tet operator (O 2 ) placed immediately after the transcriptional start sites of VACV genes, thereby blocking transcription (12, 17, 18) . In an effort to obtain the lowest basal levels of expression and the highest inducibility in this system, we generated recombinant VACVs constitutively expressing the tetR gene under a strong early/late synthetic VACV promoter (P E/L ) (19) and the red fluorescent protein DsRed-Express (DsRed) gene under several different Significance Replication-competent Vaccinia virus (VACV) vectors are widely used in the development of vaccines and therapeutics to control infectious diseases, cancer, and even fertility; however, as with all live vaccines, there are safety concerns. In this study, we developed a safety mechanism for VACV based on the conditional expression of a protective gene (IFN-γ) under a tightly controlled tetracycline-inducible promoter. We showed that immunodeficient mice are protected from a lethal VACV infection when treated with tetracyclines. This strategy has the potential to allow treatment of any complications that may result from VACV replication to be as simple as standard antibiotic regimens. Such "SMART" VACV vectors have broad applications in the fields of vaccinology and cancer therapy. engineered inducible promoters (Fig. 1A) . A VACV early transcription termination signal (TTTTTNT) present in the middle of the tetR gene was disrupted by silent mutation to ensure early expression of TetR, which would avoid leaky expression from tet-controlled promoters. The engineered inducible promoters included the P 11 late promoter (the natural promoter for the VACV F17R gene) (20) and the synthetic early/late promoter (P E/L ) (19) with either one or two copies of the O 2 operator separated by 2 bp or 11 bp, or one copy each of the O 1 and O 2 operators separated by 11 bp (Fig. 1 B and C) . These strategies were chosen based on the fact that TetR binds the O 2 operator with a threefold to fivefold greater affinity compared with the O 1 operator (21, 22) , that two copies of the O 2 operator separated by 2 bp have been used successfully in mammalian expression systems (23) , and that the two binding sites for TetR in its native transposon Tn10 tet operon (O 1 and O 2 ) are separated by 11 bp (Fig. 1D) .
Fluorescence microscopy studies of isolated viral plaques formed in the presence or absence of tetracyclines showed that all inducible promoters tested expressed the reporter gene (DsRed) in the presence of DOX, but not in the absence of inducers. Fig. 2A shows representative results for a control virus not expressing DsRed (vP 11 -Control; Table 1 ), a control virus expressing high levels of DsRed constitutively (vP 11 ), and the vP 11 O 2 test virus, which did not express detectable DsRed in the absence of DOX but did express high levels in the presence of DOX. In addition, there was no difference in plaque size or number in the presence of DOX ( Fig. 2A) .
In an effort to quantify basal levels of expression, inducibility, and maximum expression levels, we infected BS-C-1 cells with the VACVs at a multiplicity of infection (MOI) of 1 in the absence or presence of multiple concentrations of DOX. At 2 d postinfection (DPI), we quantified DsRed expression using a fluorescence microplate reader (Fig. 2B) . The DsRed gene under the control of constitutive P 11 and P E/L promoters was expressed at high levels in both the absence and the presence of DOX, with slightly greater levels of expression driven by the P E/L promoter compared with the P 11 promoter. In the absence of DOX, all promoters under the control of tet operators resulted in background fluorescence readings indistinguishable from those of vP 11 -Control (the negative control virus for DsRed expression), suggesting that DsRed gene expression was tightly repressed regardless of the type, number, or spacing of the tet operators. In the presence of ≥1 ng/mL DOX, the P E/L tet operatorcontrolled promoters showed evidence of DsRed expression, which was observed in the P 11 -based promoters only at ≥10 ng/mL DOX. At 100 ng/mL DOX, DsRed expression levels for all inducible promoters were very high, but slightly lower than in control viruses constitutively expressing DsRed. The expression levels at 1,000 ng/mL DOX were identical to the levels at 100 ng/mL DOX. Thus, expression of DsRed by the inducible tet operon-controlled promoters was dosedependent, detectable only in the presence of DOX, and at ≥100 ng/mL DOX only marginally lower than that of their constitutive promoter counterparts.
Inducible Expression of IFN-γ Is Tightly Regulated In Vitro. Based on the results obtained with DsRed, we developed VACVs expressing the murine IFN-γ gene under the P 11 , P E/L , P 11 O 2 , and P E/L O 2 promoters, along with control viruses constitutively transcribing a synthetic murine IFN-γ gene lacking in-frame start codons (Table 1) . We tested the expression of bioactive murine IFN-γ by infecting HeLa S3 cells with the VACVs at an MOI of 10 in the absence or presence of 2 μg/mL DOX. Supernatants were harvested at 24 h postinfection, and antiviral activity was evaluated with a murine IFN bioassay.
The IFN-γ titers in supernatants of control viruses expressing IFN-γ under constitutive promoters (vP 11 -IFN-γ and vP E/L -IFN-γ) were high, whereas titers for the viruses transcribing the control gene (vP 11 -Control and vP E/L -Control) were below the detection limit ( Table 1) . As expected, expression of IFN-γ under the P 11 O 2 promoter (vP 11 O 2 -IFN-γ) was not detected in the absence of DOX (titer of <2 U/mL), and was as high as that of vP 11 -IFN-γ in the presence of DOX (2,048 U/mL). Surprisingly, IFN-γ expression by vP E/L O 2 -IFN-γ was detected in the presence (1,024 U/mL) and absence (16 U/mL) of DOX, indicating leaky expression from the P E/L O 2 promoter in the absence of DOX.
We evaluated the inducible expression of IFN-γ by the VACVs using ELISA to determine the minimum concentration of DOX required to fully induce IFN-γ expression. BS-C-1 cells were infected at an MOI of 5 and incubated in the absence or presence of multiple concentrations of DOX for 18 h, after which murine IFN-γ was quantified in supernatants with a commercial ELISA. In the absence of DOX, IFN-γ was not detected in supernatants of cells infected with vP 11 O 2 -IFN-γ, but it was detected in supernatants of cells infected with vP E/L O 2 -IFN-γ (1.2 pg/mL) ( Table 1 ). In the presence of ≥10 ng/mL DOX, both viruses expressed IFN-γ in a dose-dependent fashion, with consistently greater expression by vP E/L O 2 -IFN-γ. Expression of IFN-γ reached levels similar to those seen in control VACVs (vP 11 -IFN-γ and vP E/L -IFN-γ) at DOX concentrations as low as 40 ng/mL ( Fig.  3 and Table 1 ). Thus, expression of IFN-γ was tightly regulated under the P 11 O 2 promoter, whereas expression under P E/L O 2 was leaky, and in both cases expression was as high as that of control constitutive promoters in the presence of ≥40 ng/mL DOX.
Expression of IFN-γ Has No Effect on VACV Replication In Vitro. Expression of IFN-γ by VACV has been shown to have no effect on virus replication in vitro, even though these viruses are highly attenuated in vivo (13) (14) (15) . In addition, plaque sizes of the VACVs in the presence or absence of DOX were indistinguishable from those of control viruses in cell culture ( Fig. 2A) , as expected (12) . The kinetics of viral replication in vitro were essentially identical in all of the VACVs when determined in BS-C-1 cells infected at a low MOI (0.01) in the absence of DOX (Fig. 4) . Thus, expression of murine IFN-γ at higher (under P E/L ) or lower (under P 11 ) levels had no effect on VACV replication in vitro, and all recombinant VACVs replicated to levels comparable to the WT parental virus Western Reserve (WR). (24, 25) and were shown to not cause weight loss in a pilot study with mice. Animals were weighed daily and euthanized at ≥30% weight loss.
All animals inoculated with vP 11 -Control exhibited severe weight loss after infection (Fig. 5A ) and were euthanized between 8 and 34 DPI (median, 22 DPI) (Fig. 6A) . Similarly, all animals inoculated with vP 11 O 2 -IFN-γ in the absence of DOX were euthanized between 19 and 38 DPI (median, 26 DPI), not statistically different than the vP 11 -Control group. However, animals inoculated with vP 11 O 2 -IFN-γ in the presence of DOX exhibited no weight loss and survived, with the exception of 1 of the 10 inoculated animals that had to be euthanized at 14 DPI owing to a physical injury likely unrelated to VACV infection. This profile matched the 9 out of 10 animals from the group inoculated with vP 11 -IFN-γ that also exhibited no weight loss and survived infection. One animal showed signs of neurologic problems but no weight loss at 6 DPI, possibly owing to an unrelated condition, and was euthanized.
Statistical analyses indicated significant differences in weight (P ≤ 0.001 starting at 6 DPI, two-way repeated-measures ANOVA) and survival (P ≤ 0.0001, log-rank test) between these two groups and the vP 11 -Control and vP 11 O 2 -IFN-γ groups in the absence of DOX. After addition of DOX to drinking water was discontinued at 22 DPI, all surviving animals in the vP 11 O 2 -IFN-γ group that had received DOX continued to gain weight up to 41 DPI, when the experiment was terminated (Fig. 5A) , suggesting that VACV was cleared in this group of animals. Thus, in the absence of DOX, vP 11 O 2 -IFN-γ replicated fully in vivo and caused severe weight loss in SCID mice (comparable to vP 11 -Control), but in the presence of DOX, the expression of IFN-γ completely protected mice from the lethal VACV infection.
All animals inoculated with vP E/L -Control sustained severe weight loss after infection ( Viruses were grown in HeLa S3 (for bioassay) or BS-C-1 cells (for ELISA) in the absence (-) or presence (+) of DOX at 2 μg/mL for bioassay and 10 ng/mL for ELISA. ‡ Average IFN-γ titer (± SEM if applicable) in supernatant of infected cells. The detection limit was 2 U/mL for bioassay and 1 pg/mL for ELISA.
22 and 34 DPI (median, 32 DPI) (Fig. 6B) . Remarkably, all animals inoculated with vP E/L O 2 -IFN-γ, including those inoculated in the absence of DOX, exhibited no weight loss and survived infection. This result was likely related to the low (leaky) levels of murine IFN-γ expression under the inducible P E/L O 2 promoter in the absence of inducer (Table 1) .
Discussion

Replication-competent VACVs are useful for the development of oncolytic viral therapies and elicit superior immune responses when used as vaccine and immunotherapeutic vectors (4, 26).
Safety is a major concern, however, owing to the potential complications that can result from VACV inoculation in both vaccinees and their contacts. Here we propose an approach that retains the full replication competency of the virus in vivo, which is essential to maintaining its oncolytic potential and high efficacy as a vaccine and immunotherapeutic vector. At the same time, this system has the potential to allow treatment of complications resulting from virus replication to be as simple as standard antibiotic regimens.
To accomplish this goal, we first constructed multiple VACV vectors expressing the tetR gene under a strong constitutive VACV promoter and a reporter gene (DsRed) under engineered tetracycline-inducible promoters (Fig. 1) . These promoters were capable of expressing detectable levels of DsRed in the presence, but not in the absence, of tetracyclines such as DOX (Fig. 2) . We then constructed SMART VACVs inducibly expressing murine IFN-γ and found that IFN-γ was not detected when expressed under a P 11 O 2 -based promoter in the absence of DOX in either an IFN bioassay or sensitive quantitative ELISA (Fig. 3) . Under the P E/L O 2 -based promoter, however, low but measurable levels of IFN-γ could be detected in vitro, most likely owing to leaky early expression from that promoter.
Considering that we were able to control expression from the late P 11 O 2 -based promoters (Figs. 2 and 3) , leaky expression from the P E/L O 2 -based promoters was likely related to unregulated early expression. This is not surprising, given that TetR begins to accumulate in infected cells early in the course of infection and might not have reached levels that could effectively bind the P E/L O 2 promoter operator and shut down early gene expression. Regardless, DsRed expression under the P E/L tet operon-based promoters was not detected by fluorescence microscopy or fluorometry (Fig. 2) , indicating that IFN-γ expression is likely a more sensitive method for detecting leaky expression. Finally, levels of IFN-γ expression under inducible promoters were comparable to levels expressed under constitutive promoters at relatively low concentrations (≥40 ng/mL) of DOX (Fig. 3) , and all VACV vectors replicated indistinguishably from the parental WR vector in vitro (Fig. 4) .
We used infection of highly susceptible immunodeficient mice with the SMART VACVs as a model to test the potential efficacy of antibiotic induction of a therapeutic protein to protect against VACV complications. Intraperitoneal inoculation of immunodeficient nude or SCID mice is an established, sensitive model of disseminated VACV infection; doses as low as 100 PFU of the WR strain of VACV can be 100% lethal (27, 28) . We inoculated SCID mice with the VACVs and assessed weight loss and survival in the presence or absence of DOX (Figs. 5 and 6 ). In the absence of DOX, mice receiving a VACV with the IFN-γ gene under the P 11 Hours post-infection Titer (PFU/ml) 
. Inducible expression of IFN-γ protects SCID mice from weight loss due to VACV infection. Groups of C.B-17 SCID mice were inoculated i.p. with 10 7 PFU of the indicated VACVs in the absence or presence of DOX, as indicated. When present, DOX was dissolved in drinking water (2 mg/mL) and offered starting at 2 d before inoculation and continuing up to 22 DPI (shaded area). Animals were weighed daily and euthanized at ≥30% weight loss. Mean weights are shown before and after infection for VACVs expressing IFN-γ under P 11 -based promoters (A) and under P E/L -based promoters (B), plus appropriate controls. Error bars indicate SEM. All groups consisted of 10 animals except the vP E/L -Control group, which comprised 7 animals. * , † P ≤ 0.001, two-way repeated-measures ANOVA followed by the Holm-Sidak multiple-comparisons test for differences between the groups that gained weight and the groups that lost weight starting at 6 DPI (*) or 8 DPI ( † ).
expression of IFN-γ from the P E/L O 2 promoter and was somewhat unexpected, given previous evidence indicating that lower expression levels of IFN-γ under a weaker early/late promoter (P 7.5 ) were not as protective in immunodeficient nude mice (15) . Nevertheless, this study demonstrates that even very low levels of IFN-γ can completely protect SCID mice from lethal VACV infection. Our proof-of-concept study demonstrates that inducible expression of IFN-γ in VACV can be tightly controlled, and that oral administration of antibiotics can protect immunodeficient mice from lethal VACV infection. This built-in safety mechanism has the potential to positively impact the development of nextgeneration, replication-competent VACV vaccines and therapeutic vectors, possibly allowing treatment of complications from vaccination or therapy to be as simple as standard tetracycline antibiotic treatment. The effect on vaccine or therapeutic efficacy should be minimal, because IFN-γ would be expressed only if induction with tetracyclines was required. Because IFN-γ would be expressed at the actual sites of viral replication, this strategy could be more effective than other treatments for poxvirus infections, such as antivirals (29) .
One approach to test the effectiveness of this mechanism in vaccine and therapeutic animal models would be to design VACV oncolytic vectors able to replicate and destroy human tumor xenografts in immunocompromised mice, thereby creating an animal model for testing VACV efficacy in human tumors. In this model, therapy would need to be stopped after inoculation by induction of IFN-γ with tetracyclines, or otherwise the immunodeficient mice would succumb to VACV infection. Because IFN-γ is known to have direct and indirect antitumor activities (30) , such an oncolytic vector could provide additional therapeutic benefits after induction. Generation of the VACVs. A schematic representation of the VACV transfer vector backbone used for the generation of the recombinant VACVs is shown in Fig. 1A . We first constructed a set of plasmid transfer vectors containing the DsRed gene under different inducible promoters. The vectors were constructed in multiple steps through a combination of DNA synthesis (DNA2.0), PCR cloning, and annealing of complementary oligonucleotides (Invitrogen), using engineered restriction endonuclease sites to facilitate cloning. The gpt-gus fusion gene for combined gpt selection and gus screening was developed by PCR cloning of the gusA gene from plasmid pBI221 (Clontech) using a previously developed strategy (31) . The gpt gene was synthesized based on the sequence in plasmid pMSG (GenBank accession no. U13860) under a synthetic early/late VACV promoter (P sel , sequence AATTGGATCAGCTTTTTTTTTTTTTTTTTTGGCATATAAATAAGGTCGAAGCTTG-GTACCAAAAATTGAAAAACTATTCTAATTTATTGCACG) (32), together with left and right sequences of the VACV thymidine kinase (TK) gene (∼500 bp each, based on GenBank accession no. AY243312) to direct homologous recombination and insertional inactivation of the TK gene. The tetR gene (based on GenBank accession no. X00694) was synthesized under the P E/L synthetic promoter (sequence TTAAAAATTGAAATTTTATTTTTTTTTTTTG-GAATATAAATA) (19) , with an internal early transcriptional termination sequence (TTTTTNT) removed from the middle of the gene (Leu codon at position 358 changed from TTA to CTT) to ensure early gene expression. The DsRed gene (based on the pDsRed-Express sequence; Clontech) was synthesized under a modified P 11 late VACV promoter (sequence ATATAGTAGAATTTCATTTTG-TTTTTTTCTATGCTATAAATA) or the synthetic P E/L promoter (19) .
Materials and Methods
Different combinations of the tet operators O 1 and O 2 (21) were placed immediately after the P 11 and P E/L promoters ( Fig. 1 B and C) with synthetic annealed oligonucleotides. In some transfer vectors, the DsRed gene ( Fig. 1 ) was replaced with a synthetic murine IFN-γ gene sequence (based on GenBank accession no. K00083). A control murine IFN-γ gene was also synthesized to generate appropriate control viruses not expressing IFN-γ by replacing four in-frame ATG start codons and two in-frame alternative GTG start codons (33) with other codons. All transfer vectors were sequenced after synthesis, PCR cloning, or oligonucleotide annealing to confirm sequence identity. Recombinant VACVs were generated by standard homologous recombination as described previously (15) . Viral Growth Kinetics. Viral replication was determined by generating growth curves at a low MOI. In brief, triplicate monolayers of BS-C-1 cells were infected with VACV at an MOI of 0.01 for 1 h in 12-well plates, and virus replication was determined as described previously (34) . Virus titers were then determined by a plaque assay on BS-C-1 cells, in duplicate.
Fluorescence Microscopy. BS-C-1 cell monolayers in six-well plates were infected with the VACVs (35 PFU/well) in the absence or presence of 1 μg/mL tetracycline or DOX (Sigma-Aldrich). DsRed expression was determined by imaging plaques at 36 h postinfection under a Nikon Eclipse TS100-F inverted microscope. PFU of the indicated VACVs in the absence or presence of DOX, as indicated. When present, DOX was dissolved in drinking water (2 mg/mL) and offered starting at 2 d before inoculation and continuing up to 22 DPI. Animals were weighed daily and euthanized at ≥30% weight loss. Percent survival is shown before and after infection for VACVs expressing IFN-γ under P 11 -based promoters (A) and under P E/L -based promoters (B), plus appropriate controls. All groups consisted of 10 animals except the vP E/L -Control group, which comprised 7 animals. *P ≤ 0.0001, log-rank test, for differences in survival between the specified groups.
Murine IFN-γ Bioassay and ELISA. The antiviral activity of IFN-γ in VACVinfected supernatants was determined by an IFN bioassay based on the prevention of the cytopathic effects of encephalomyocarditis virus on murine L-929 cells (35) . In brief, HeLa S3 cells in 24-well plates were infected with the VACVs at an MOI of 10 in triplicate and then incubated in the absence or presence of 2 μg/mL DOX. At 24 h postinfection, supernatants were harvested and filtered through 0.2-μm filters, and IFN-γ titers were determined as described previously (15) . In addition, BS-C-1 cells in 12-well plates were infected with the VACVs at an MOI of 5 in triplicate and then incubated in the absence or presence of multiple concentrations of DOX for 18 h in a final volume of 1 mL. Aliquots of the collected supernatants were used to measure the concentration of murine IFN-γ with a commercial ELISA (eBioscience).
Infection of Immunodeficient Mice. SCID mice (C.B-17, C.B-Igh-1 b /IcrTacPrkdc scid ) were purchased from Taconic Farms. All animals were maintained according to animal care protocols approved by the Institutional Animal Care and Use Committee. Mice (7-wk-old males) were divided into groups. Starting at 2 d before inoculation, some groups received DOX in drinking water (2 mg/mL without sweetening) (36) , provided ad libitum up to 22 DPI. During this period, water bottles were replaced with freshly prepared DOX solution every 2 d (37). Animals were inoculated i.p. with 10 7 PFU of the VACVs in a final volume of 250 μL of sterile PBS. Animals were examined and weighed daily. Those exhibiting ≥30% weight loss, evident progressive paralysis, or severe distress were removed and euthanized. At 41 DPI, the experiment was terminated, and surviving animals were euthanized by CO 2 overdose.
Statistical Analysis. Statistical analyses were performed with GraphPad Prism version 6.0c.
